logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise subsidiary Talem Therapeutics forms scientific advisory committee

The committee will investigate and select potential antibody targets for discovery and deliberate on possible partnerships

Scientists meeting
The committee’s term is set to last for three years, with the goal of establishing a strong pipeline and a network of partners

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPAFT) subsidiary Talem Therapeutics has formed a committee to oversee the development of its scientific pipeline, the company announced Thursday.

The High-Value Target Scientific Committee will investigate and select potential antibody targets for discovery and deliberate on possible partnerships.

The committee’s term is set to last for three years, with the goal of establishing a strong pipeline and a network of partners.

READ: ImmunoPrecise inks new agreement to use proprietary screening platform in cancer therapy

Members include Ilse Roodink of ImmunoPrecise Europe, Zalan Szabo of Immuno-owned U-Protein Express, Andra Li of ImmunoPrecise Canada and ImmunoPrecise CEO Jennifer Bath. Additional members are expected to be added.

Talem Therapeutics is focused on the discovery of new antibodies, and plans to develop drug candidates related to neurology, immuno-oncology, gastroenterology, inflammation, and other rare diseases.
    
Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 0.52 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $35.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 04/02/2019

2 min read